As there are only limited MRD monitoring markers for the AML-NK patients, such as NPM1 and FLT3-ITD mutations, overexpression of the oncogenes (FLT3, MYB, DNMT3B, and MYCN) can be useful in MRD monitoring, especially in cases with no genetic aberrations. The gene discussed is NPM1; the disease is acute myeloid leukemia.